The genetic contribution of the natriuretic peptide system to cardiovascular diseases.
Three types of natriuretic peptides (NP) have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). The NP family elicits a number of vascular, renal and endocrine effects that help to maintain blood pressure and extracellular fluid volume. These effects are mediated by the specific binding of NP to cell surface receptors that have been characterized, purified and cloned from cells of the vasculature, kidney, adrenal gland and brain. There are 3 subtypes of NP receptors: type A natriuretic peptide receptor (NPRA), type B natriuretic peptide receptor (NPRB), and type C natriuretic peptide receptor (NPRC). All 3 subtypes affect cellular second messenger activity. NPRA and NPRB are guanylyl cyclase receptors, and their activation increases cGMP levels. Activation of NPRC results in inhibition of adenylyl cyclase activity. Human NPRA has a high structural homology with human NPRB, and contains a highly-conserved guanylyl cyclase domain. ANP and BNP bind primarily to NPRA, which is found in the vasculature, causing vasodilation and inhibition of vascular smooth muscle cell proliferation. The present paper contains a review of NPs and their receptors and the genetic contribution of the NP system to cardiovascular diseases such as essential hypertension and myocardial infarction.
Nakayama
Tomohiro
T
Division of Receptor Biology, Advanced Medical Research Center, Nihon University School of Medicine, Ooyaguchi-kamimachi, Tokyo, Japan.
D000818:Animals; D002318:Cardiovascular Diseases / Q000235:genetics / Q000503:physiopathology*; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D008024:Ligands; D009154:Mutation; D045265:Natriuretic Peptides / Q000235:genetics* / Q000378:metabolism*; D018000:Receptors, Peptide / Q000378:metabolism
D008024:Ligands; D045265:Natriuretic Peptides; D018000:Receptors, Peptide